Saturday, September 07, 2019 7:27:42 AM
What else stood out is the # of patients that posi would be able to treat in these other cohorts. The abstract indicates 3.6% of exon 18 insertions are affected which is, low and behold, the same amount of ex20in lung cancer patients. There are 7700 exon 20 in NSCLC patients in the US (20,700 worldwide). Double these #s again if you use the basket trial population. I don’t have a handle on the # of osimertinib-resistance mutation patients that posi would be able to treat yet but I would surmise similar # s. Bottom line is, the patient population that posi will be able to treat is ever expanding and it’s just a matter of time till Wall Street sees that.
Recent SPPI News
- Form 15-12G - Securities registration termination [Section 12(g)] • Edgar (US Regulatory) • 11/09/2023 10:00:17 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 09/28/2023 04:15:27 AM
- Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments • Edgar (US Regulatory) • 09/26/2023 09:23:08 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM